From cardiovascular adverse events to complex dosing regimens, oncology trials present unique safety-related considerations. Left unaddressed, they could undermine a trial or put patient safety at risk. In this paper, we discuss some of those issues and how sponsors can best address them.
New Blog: "Ask the IRB Experts"Visit Blog
Other content in this Stream
A Fresh Perspective from the FDA on the Final IND Safety Reporting Rule
WCG’s SafetyVigilance® Online Safety Event Solution Delivers Quality and Efficiency to Unify Enterprise Trial Management and Meet Regional Guidelines and Regulations
Our experts teamed-up to take on your safety questions and provide you with tactics and strategies to overcome the biggest challenges plaguing your studies today.
Custom-built to streamline the adjudication process, the AIMS platform allows for enhanced endpoint adjudication capabilities.